ACET.O (ACET.O) News
Track canonical SquawkNews coverage tagged to ACET.O, ACET.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Adicet Bio reports positive safety, efficacy data from prula-cel lupus study
The company said prula-cel was well tolerated, with no CRS above grade 2 and no IEC-HS or ICANS. It plans pivotal lupus nephritis trial start-up activities in Q4 2026 and expects a further data update in mid-2027.
EQUITY | Sep 28, 2026, 10:50 AM UTC
M
Adicet Bio says prula-cel Phase 1 lupus study shows 54% DORIS remission at 12 months
Company says patients also showed sustained disease control, broad discontinuation of immunosuppressants and steroid tapering.
EQUITY | Sep 28, 2026, 10:46 AM UTC
L
Adicet Bio announces positive prula-cel lupus study safety, efficacy data
The Phase 1 study of prulacabtagene leucl (prula-cel) in systemic lupus erythematosus with or without lupus nephritis showed no CRS above Grade 2, no ICANS and no IEC-HS. At 12 months, 54% of evaluable patients achieved
EQUITY | Sep 28, 2026, 10:46 AM UTC